# Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

> **NCT04552847** · PHASE2,PHASE3 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 85 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Al18F-NOTA-octreotide
- **DEVICE:** PET/CT
- **DEVICE:** PET/MR

## Key facts

- **NCT ID:** NCT04552847
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-07
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-02-08
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2022-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552847, "Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04552847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*